Michele Murphy
Family · Winter Haven, FLNPI 1821453044
Payments from drug & device makers
Across 218 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$420
- Pfizer$403
- Novo Nordisk$319
- AbbVie$310
- Lilly USA, LLC$266
- Amgen$239
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,824100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $420 |
| Pfizer | 26 | $403 |
| Novo Nordisk | 19 | $319 |
| AbbVie | 16 | $310 |
| Lilly USA, LLC | 15 | $266 |
| Amgen | 16 | $239 |
| GSK | 14 | $232 |
| Boehringer Ingelheim | 9 | $177 |
| Eisai Inc. | 7 | $175 |
| Novartis | 7 | $136 |
| Merck | 6 | $121 |
| Bayer | 5 | $111 |
| Biohaven Pharmaceuticals, Inc. | 4 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Johnson & Johnson | 4 | $70 |
| Exact Sciences | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Dexcom, Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Abbott | 2 | $42 |
| Shield Therapeutics Inc | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 3 | $34 |
| Scilex Pharmaceuticals Inc. | 2 | $33 |
| Boston Scientific | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Nevro Corp. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$3,824 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $83,029 |
| OzempicSemaglutide | 25 | $35,295 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $34,477 |
| JardianceEmpagliflozin | 29 | $31,244 |
| FarxigaDapagliflozin Propanediol | 36 | $28,376 |
| TrulicityDulaglutide | 13 | $23,700 |
| MounjaroTirzepatide | 19 | $22,570 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $21,674 |
| JanuviaSitagliptin Phosphate | 13 | $20,418 |
| XareltoRivaroxaban | 11 | $9,840 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,942 |
| Gabapentin | 194 | $3,404 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,136 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $2,918 |
| Omeprazole | 187 | $2,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $403 | $83,02988 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $266 | $46,26932 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $177 | $37,18640 claims |
| Novo NordiskOzempic | $319 | $35,29525 claims |
| GSKTrelegy Ellipta | $232 | $34,47738 claims |
| AstraZenecaFarxiga, Symbicort | $420 | $31,51247 claims |
| MerckJanuvia | $121 | $20,41813 claims |
| Johnson & JohnsonXarelto | $70 | $9,84011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Winter Haven
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.